Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Conditions:   Neoplasms;   Esophageal Neoplasms;   Esophagus Neoplasm;   Esophagus Cancer;   Neoplasms, Esophageal;   Esophageal Cancer (EsC) Interventions:   Drug: Nivolumab;   Drug: Entinostat;   Biological: Montanide(R) ISA-51 VG Adjuvant;   Biological: H1299 Cell Lysates Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials